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Clinical Issues Surrounding Once-Daily Aminoglycoside Dosing in Children 
 
Chad A. Knoderer, Pharm.D., Julie A. Everett, Pharm.D., and William F. Buss, Pharm.D 
 
Aminoglycoside antibiotics are first-line treatment for many infectious diseases in the pediatric 
population and are effective in adults. The traditional dosing interval in children is every 8–12 hours. 
Studies in adults reported equivalent efficacy and equal or less toxicity with once-daily regimens. Despite 
many studies in the adult population, this approach has yet to become standard practice in most pediatric 
hospitals. Reasons for lack of acceptance of this strategy in children include rapid aminoglycoside 
clearance, unknown duration of postantibiotic effect, safety concerns, and limited clinical and efficacy 
data. 
 
Aminoglycoside antibiotics are first-line treatment for many gram-negative infections in 
children. Over the past several years, studies performed in adults changed the manner in which 
these drugs are dosed. Traditionally, aminoglycosides were administered several times/day to 
both adults and children. Data from adult studies indicate the safety and efficacy of once-daily 
dosing (ODD) and prompted some clinicians to change to that practice. Results of randomized 
trials and meta-analyses in adults indicate that ODD is no less effective than traditional dosing 
and may be associated with an equal or lower frequency of nephrotoxicity.
1-13 
 
According to one study, extended-interval aminoglycoside dosing was used in 75% of all acute 
care hospitals responding to a mailed questionnaire.
14
 Although ODD has become prevalent in 
many adult settings, it is not widely used in the pediatric setting. Of hospitals responding to the 
questionnaire, only 23% used extended-interval dosing for patients aged 1- 18 years.
14
 Several 
questions arise when contemplating ODD in children; namely, optimum dosage, interval, and 
monitoring. Other important considerations are efficacy, safety, and length of time that serum 
concentrations are below the minimum inhibitory concentration (MIC) for the microorganism. 
 
Pharmacology 
 
Mechanism of Action 
 
Aminoglycosides as a class have bactericidal activity against a broad spectrum of gram negative 
organisms, including Pseudomonas aeruginosa. By irreversibly binding to the 30S bacterial 
ribosome, the agents inhibit bacterial protein synthesis. This action requires an energy- and 
oxygen-dependent transport mechanism into the bacterial cell.
15 
 
Pharmacodynamics 
 
Unlike β-lactam antibiotics, which require a continuous time above MIC for maximum bacterial 
killing, bactericidal activity of aminoglycosides is concentration dependent. 
15–17
 As the peak 
serum concentration of the drug increases, bacterial killing is increased. It is not known at what 
peak serum concentration bacterial killing is maximized. In early studies, peak concentrations 
greater than 5 μg/ml for gentamicin and tobramycin, and greater than 20 μg/ml for amikacin 
were associated with decreased mortality from gram-negative bacteremia.
18
 In addition, 
successful outcome from gram-negative pneumonia was significantly increased in patients with 
peak serum concentrations of 7 μg/ml or more for gentamicin and tobramycin and 28 μg/ml for 
amikacin. 19 In one study clinical cure of gram-negative pneumonia was greatest when 
gentamicin peak concentrations were 8 μg/ml or more. 20 Clinical cure was 89% compared with 
43% in patients with a peak concentration of 8 μg/ml or more, and less than 8 μg/ml, 
respectively. 20 Subsequent studies reported that the serum peak concentration:MIC ratio 
(peak:MIC) rather than peak concentration alone was more strongly associated with a positive 
clinical response in patients infected with gram- negative organisms.21 Clinical response rates of 
approximately 90% could be achieved with a peak:MIC ratio between 8 and 10:1. 21 The theory 
is that bactericidal effects of aminoglycosides with traditional dosing can be maximized when 
the ratio is between 8 and 10:1. 16, 22This ratio may not be achieved consistently when 
traditional dosing is used for organisms that are intermediately susceptible or resistant to the 
drugs; however, it should be achieved more reliably with ODD. 
 
Adaptive Resistance 
 
Adaptive resistance is a reversible diminished bacterial response to aminoglycosides appearing 
after first exposure of bacteria to the drug. Aminoglycosides have biphasic bactericidal kinetics. 
The initial phase invokes rapid concentration-dependent bacterial killing, and the second phase is 
characterized by slow concentration-independent bacterial killing. 
23–26 
Adaptive resistance 
develops during the second phase due to downregulation of drug uptake into the bacterial cell 
and causes impermeability to all aminoglycosides. 23, 24 It was first shown by in vitro studies 
with P. aeruginosa strains. 
23
 It also developed in vivo in neutropenic mice exposed to netilmicin 
30 mg/kg after start of infection. 
24
 The three study groups were not redosed, given one 
additional 20-mg/kg dose, or given a 20-mg/kg dose every 2 hours for five doses. The first and 
second (of five) doses of netilmicin reduced the number of colony-forming units (cfu), but the 
three additional doses given 4, 6, and 8 hours after the first dose produced no detectable bacterial 
killing. 
24
 The cfu/mouse thigh began to increase 6 hours after the first drug exposure despite a 
plasma concentration above MIC. 
24
 The unresponsiveness to additional netilmicin doses was 
reversed within 8 hours of the final dose. 
The mouse half-life of netilmicin in that study was 25 minutes or less. 24 Dosing 
aminoglycosides once every 4–5 half-lives in mice simulates comparable dosing of every 8 hours 
in children and adolescents. This is based on knowledge that the agents’ half-lives in children 
and adolescents with normal renal function are approximately 1.5–2.5 hours. 27 Therefore, the 
theoretical clinical implication of adaptive resistance studies is that maintaining the 
aminoglycoside concentration persistently above MIC may provide no additional benefit. 
 
A relatively drug-free interval may reduce or reverse adaptive resistance and may improve 
bacterial killing. In our experience, trough concentrations with traditional dosing in children 
sometimes may fall below MIC, but concentrations that are equal to or above MIC also have 
been observed. Comparatively, ODD can more reliably achieve a relatively drug-free interval 
due to extended dosing intervals. In this setting, traditional dosing theoretically would not have 
additional bactericidal benefit. In addition, it would have less potential to reduce or reverse the 
development of adaptive resistance. 
 As adaptive resistance has been studied only in vitro and in animal models, it is unclear whether 
this relatively drug-free interval with ODD will offer a therapeutic advantage. The optimal length 
of this drug-free interval has not been identified. If it is excessive, it actually may result in 
clinically significant bacterial regrowth even to the level of the first bacterial inoculum. 24 It is 
possible that ODD could prolong the drug-free interval given the short half- lives of 
aminoglycosides in children.  
Postantibiotic Effect 
The postantibiotic effect (PAE) is persistence of antimicrobial action with minimal concentration 
of drug. 
28, 29
 It originally was observed in vitro but also was seen in in vivo animal studies. 
Although it is thought to occur in humans, a significant in vivo PAE in humans has not been 
demonstrated. A number of factors such as type of organism, drug concentration, and class of 
antimicrobial can effect the duration of the PAE.
29
 Aminoglycosides have a significant PAE with 
gram-negative organisms. In neutropenic mice, the PAE duration for various gram-negative 
organisms was 1.4–7.3 hours after gentamicin 8 mg/kg. 3 Strains of Klebsiella pneumonia have 
consistently longer PAEs than strains of Escherichia coli.
30, 31
 In addition, increased doses of 
tobramycin led to longer PAEs for  P. aeruginosa and  K. pneumonia in mice. 31 Data in 
humans are limited. After doses of amikacin 15 and 30 mg/kg, the in vitro PAE duration for 
gram-negative organisms ranged from 1 to more than 2 hours in humans. 
32
 This study also 
showed a direct relationship between drug concentration and PAE. 
 
Toxicity 
 
Nephrotoxicity 
 
A significant concern with aminoglycosides in adults as well as children is nephrotoxicity. Few 
data are available on the frequency or clinical impact of nephrotoxicity in children receiving 
traditionally dosed aminoglycosides. The disorder occurs as a result of an interaction of the drug 
in the renal tubule, causing reversible tubular necrosis and decreased glomerular filtration.
15, 33
 
One hypothesis regarding the mechanism is that a small portion of the aminoglycoside is stored 
in the tubular cell lysosome after reabsorption from the proximal tubule. Toxicity is then 
dependent on the local concentration within the lysosome. Another hypothesis is that once the 
drug concentration in the lysosome reaches a threshold level, the drug is released and directly 
causes cellular toxicity. 
33, 34 
 
Uptake of certain aminoglycosides is a saturable process. 
34–36
 Cortical uptake of netilmicin and 
gentamicin was saturable in rats, and compared with single injections, continuous infusions led 
to 30% and 50% higher cortical concentrations, respectively. 
34
 In contrast, renal cortex 
accumulation of tobramycin did not have saturable kinetics in rats but was linearly related to 
serum concentrations. 
35
 In humans, however, cortical concentrations of tobramycin were lower 
after single injections than multiple injections or continuous infusions. 
36 
Renal cortex 
concentrations of gentamicin, amikacin, and netilmicin were lower in humans after 
administration of identical daily doses as single injections versus multiple injections or 
continuous infusions. 
35, 36
 Area under the curve (AUC) was not significantly different among 
dosing methods. 
34, 36
 Renal accumulation and toxicity of aminoglycosides in humans may be 
decreased with one daily dose based on evidence of saturable cortical uptake. Increased trough 
serum concentrations of aminoglycosides are directly related to nephrotoxicity, but high peak 
serum concentrations are not.
37
 Other risk factors are duration of therapy, daily drug AUC, and 
concurrent nephrotoxic drugs. 
37–39
 Studies that compared ODD with traditional dosing in adults 
reported either a decreased frequency or no difference in nephrotoxicity.
1–13, 38, 39
 
 
Ototoxicity 
 
Another significant adverse effect of aminoglycosides is ototoxicity. As with nephrotoxicity, 
data are lacking regarding this adverse effect and its frequency in children. All drugs in this class 
may induce ototoxicity that can manifest as cochlear or vestibular symptoms. 
15
 The exact 
mechanism is not known but is thought to be an interaction between the agents and hair cell 
membranes in cochlear and vestibular receptors.
40,41
 The interaction causes degenerative changes 
in the hair cell, possibly altering its structure and permeability. Many risk factors for ototoxicity 
have been proposed and/or identified, including aminoglycoside accumulation, renal impairment, 
length of therapy, age, dosage, and concurrent administration of ototoxic agents. 
42
 The literature 
has not clearly established the relationship, if any, between peak and trough concentrations and 
auditory or vestibular toxicity. 
 
One study examined the relationship of a number of factors with aminoglycoside associated 
ototoxicity. 
43
 Data were collected on peak and trough serum drug concentrations, total dose, 
duration of therapy, age, and other factors. After logistic regression, only older age was a 
significant risk factor for this side effect. 
43
 
 
Rationale for Once-Daily Dosing 
 
Traditionally, aminoglycoside antibiotics were dosed several times/day. Dosing in children with 
normal renal function is usually every 8 hours but is occasionally every 6 hours. The agents 
generally are given less frequently in term and preterm neonates due to decreased and possibly 
underdeveloped renal function. 
27
 The rationale for ODD in patients with normal renal function 
is based on pharmacodynamic principles inherent to aminoglycosides, especially two key points. 
 
First, higher peak serum concentrations will be achieved with administration of higher doses. 
Since the drugs’ bactericidal effect is related to peak concentrations, higher doses will achieve a 
higher peak concentration and ensure efficacy of therapy. With this dosing, it is possible to 
achieve the desired peak:MIC ratio of 8–10:1 even for intermediately susceptible organisms with 
high MICs. This ratio may not always be achievable with traditional dosing, especially if treating 
intermediately susceptible organisms. Even though the exact duration of the PAE in humans is 
questionable, efficacy of ODD is comparable to traditional dosing. As mentioned, administration 
every 24 hours should, in theory, minimize development of adaptive resistance. 
23, 24
 
 
Second, it is thought that ODD may reduce the frequency of nephrotoxicity since low or 
undetectable trough concentrations will be attained. The rationale of ODD seems logical based 
on the key points presented. However, many questions remain regarding ODD in infants, 
children, and adolescents. 
 Efficacy in Children 
 
Extended-interval aminoglycoside dosing was studied in approximately 700 infants and children 
over 1 month of age (Table 1). 
6, 11, 44–56
 This regimen also was investigated in neonates up to 1 
month of age but is not discussed here due to the decreased renal function in that patient 
population. Infectious processes included neutropenic fever, suspected or confirmed gram-
negative infections, cystic fibrosis, and suspected or confirmed surgical infections. Nine studies 
evaluated clinical and/or microbiologic efficacy of ODD in approximately 450 children (Table 
2). 
44–51
 It is important to note that the studies were not adequately powered to show a true 
statistical difference due to a limited number of subjects. 
 
Clinical Efficacy 
 
Five studies compared the clinical efficacy of aminoglycosides administered as one or multiple 
daily doses. 
44–48
 Three of them examined gentamicin, and one each tobramycin and amikacin. 
Clinical cure rates ranged from 88–92% and 90–98% in patients receiving once- daily and 
multiple daily doses, respectively. Clinical cure was achieved in 141 (93%) of 151 and 145 
(95%) of 153 patients, respectively. 44–47 Two trials 44, 45 considered clinical cure to be 
resolution of signs and symptoms of infection. One defined the need for alternative parenteral 
antibiotics as either clinical failure or complication of original therapy. 
44
 Other trials defined 
failure to respond as persistence of fever and continuing neutropenia after the fifth and fourth 
days of therapy. 
46, 47
 One group did not report clinical cure rates, only clinical improvement. 
48
 
 
Four additional studies evaluating clinical efficacy did not compare dosing regimens, but 
administered aminoglycosides only once/day. 
49–52
 In one trial, 76% of febrile episodes (86/113) 
responded to first-line treatment (gentamicin plus ceftriaxone) with resolution of fever after 48 
hours. 
49
 The remaining 24% of patients required vancomycin and ceftazidime due to unresolved 
fever with or without the presence of organisms resistant to first-line agents. 
49
 Others 
demonstrated 92% of febrile episodes (272/303) resolving clinically without a change in empiric 
antibiotic treatment. 
50
 Similarly, a clinical cure rate of 100% (25/25) was achieved in patients 
treated with once-daily amikacin. 
51
 In the final trial, 98% of patients receiving once-daily 
amikacin had a satisfactory clinical response after the end of treatment; however, some patients 
required additional oral (27%) or parenteral (14%) antimicrobial therapy. 
52
 
 
Microbiologic Efficacy 
 
Of studies comparing ODD with traditionally dosed aminoglycosides, only two evaluated 
microbiologic as well as clinical efficacy. 
44, 45
 In one investigation, bacteriologic eradication 
rates were 97% (58/60) and 98% (58/59), respectively, in patients treated with gentamicin 
once/day and 3 times/day. 
44
 Escherichia coli was the most common causative organism for both 
groups. Other organisms were gram-negative bacilli, enterococci, and Staphylococcus sp.  
Staphylococcus epidermidis was observed in two patients treated once/day and one treated 3 
times/day. In all of these patients, the organism was isolated in the absence of pyuria. The 
investigators considered none of the reinfection cases to be clinically significant. Similarly, 
microbiologic cure was achieved in 100% (10/10) and 92% (12/13) of patients treated with 
gentamicin once/day and 3 times/day; data regarding reinfection were not reported. 
45
 
 
 
In the most detailed data regarding microbiologic efficacy, 56 patients with documented bacterial 
infection received amikacin once/day either alone or in combination with another antibiotic.
52
 
Six classifications of infections were pneumonia (16 patients); chronic otitis (7); meningitis, 
bacteremia, septicemia (9); osteomyelitis (12); pyelonephritis (7); and peritonitis (5). Infecting 
organisms were Pseudomonas sp (27), Enterobacter sp (4), E. coli (12), Klebsiella sp (2), 
Acinetobacter sp (8), and Haemophilus influenzae (5). Some patients had multiorganism 
infections. Concomitant antimicrobials with expanded gram-negative or gram-positive spectra of 
activity were administered to 71% and 21% of patients, respectively. Bacterial eradication 
occurred in 49 (89%) of 55 patients. Six patients had persistently positive cultures after treatment 
and one was unevaluable. 
 
Microbiologic cure in patients with a variety of gram-negative infections was 100% (25/25) in 
one study.51 Cultures grew E. coli (18), K. pneumoniae (4), Enterobacter sp (1), Providencia sp 
(1), and P. aeruginosa (1). Another group reported 99 positive cultures in 96 (32%) of 303 
febrile episodes.50 Of note, 85 of those 99 cultures were documented bacteremia. 
Staphylococcus epidermidis accounted for 47% (40/85) and gram-negative organisms for only 
22% (19/85) of positive blood cultures. Treatment failed in 14% (13/96) of culturepositive 
episodes, and in 36% and 8% (p<0.001) of gram-negative and gram-positive infections, 
respectively.50 Positive blood cultures isolated one or more organisms in 29 (25%) of 113 
febrile neutropenic episodes, but microbiologic efficacy was not evaluated.
49
 
 
 
 
Toxicity in Children 
 
Nephrotoxicity 
 
Eleven studies assessed nephrotoxicity associated with ODD aminoglycoside therapy in children 
(Table 3).
44, 45, 47–55
 Most of them defined nephrotoxicity as a percentage increase in serum 
creatinine concentration over baseline or a percentage decrease in creatinine clearance from 
baseline. In addition to creatinine clearance monitoring, 24-hour proteinuria, lysozymuria, and 
B2 microglobulinuria were measured to determine nephrotoxicity.
48
 One study did not report any 
nephrotoxicity but did not detail methods used to assess the complication.
52 
 
All of the studies reported that minimal or no nephrotoxicity occurred regardless of dosing 
regimen. Overall, nephrotoxicity was evaluated in 140 (79%) of 177 and 530 (75%) of 707 
traditional and ODD treatment courses, respectively. It was not reported in any of the 140 
courses of traditional therapy but was reported in 4 (0.75%) of 530 ODD treatment courses. 
One trial defined nephrotoxicity as a rise in serum creatinine of more than 50% over baseline.
49
 
The mean serum creatinine concentration for the entire study group remained unchanged after 
gentamicin treatment. However, two episodes met criteria for nephrotoxicity. In both children 
the Hartford nomogram8 was used to change the gentamicin dosing interval to 36 hours. Serum 
creatinine returned to baseline within 14 days after discontinuation of treatment in both 
children.
49
 One case of nephrotoxicity was reported after ODD amikacin.
51
 Serum creatinine rose 
93% in a 15-month-old child with pyelonephritis and leukemia; follow-up evaluation was not 
performed. Nephrotoxicity occurred on day 14 of amikacin therapy in a child who was 
concomitantly receiving cyclosporine.
53
 The disorder resolved with discontinuation of amikacin 
and adjustment of cyclosporine dosage.
51
 
 
 
 
Ototoxicity 
 
Eight studies used audiologic assessments at baseline and at a determined follow-up point after 
aminoglycoside treatment to evaluate ototoxicity (Table 4).
44, 45, 48, 49, 52–55
 Overall, 57% 
(171/300) and 56% (83/147) of patients receiving ODD and traditionally dosed aminoglycosides, 
respectively, were assessed with an audiometric examination. Four studies reported at least one 
episode of ototoxicity, with a frequency of 8–14%.45, 49, 53, 55 In one study the side effect was not 
clinically significant55; the other three studies did not comment on clinical significance.
45, 49, 53
 
The overall frequency of ototoxicity in the eight studies was 3.5% (9/254), with it occurring in 
4.1% (7/171) and 2.4% (2/83) of patients treated with ODD and traditional regimen, 
respectively.  
 
Pharmacokinetic Analysis 
 
Six of 13 studies measuring aminoglycoside serum concentrations compared ODD with 
traditional dosing.
44–48, 54
 Peak concentrations were measured in each study 30 minutes after a 
30-minute infusion.
44–48, 54
 As expected, they were significantly higher and trough concentrations 
lower with ODD than with traditional dosing. Patients with neutropenic fever and suspected 
bacterial infection were randomized to receive gentamicin 5 mg/kg/day in one or three doses.
47
 A 
serum peak concentration greater than 10 μg/ml was achieved in 77% and 44% of the patients, 
respectively. In surgical patients, gentamicin 7.5 mg/kg/day administered as one dose was 
compared with three divided doses.54 Average peak serum concentrations were 20.4 and 7.2 
μg/ml (p<0.0001) and trough concentrations 0.29 and 0.69 μg/ml (p<0.0001), respectively. In 
febrile and neutropenic children with cancer and suspected bacteremia randomized to receive 
amikacin 20 mg/kg/day in one or two doses, mean peak concentrations were 42.6 and 19.1 μg/ml 
and trough concentrations 0.85 and 0.18 μg/ml, respectively.46 
 
 
 
Similarly high peaks and low troughs were observed in the seven studies evaluating only an 
ODD regimen.
49–53, 55, 56
 Two groups did not report the peak concentration as that obtained 30 
minutes after a 30 minute infusion.
52, 55
 One group reported the values measured 1 hour after the 
start of a 15- or 30-minute infusion.
52
 The other reported concentrations 1 hour after the dose.
55
 
Other investigators evaluated serum gentamicin concentrations measured 6–14 hours after the 
first dose and every 5 days thereafter.
49
 The Hartford nomogram8 was used to adjust gentamicin 
dosing intervals. Eight hours after the start of the infusion, all concentrations were below the 24-
hour line on the nomogram. This is not surprising, given increased aminoglycoside clearance in 
children compared with adults. In a similar study, children with fever and neutropenia 
undergoing bone marrow transplantation were treated with a single daily dose of amikacin 20 
mg/kg plus ceftazidime.53 Amikacin serum concentrations 6, 12, and 24 hours after infusion 
were undetectable (< 3 μg/ml) on days 1 and 4 of therapy. 
 
Discussion 
 
The published literature for ODD of aminoglycosides for infants and children is not as extensive 
as is that for adults. Results from studies in approximately 700 nonneonatal pediatric patients 
appear to parallel those in adult studies. However, efficacy was evaluated in only approximately 
450 of the 700 patients receiving an ODD regimen. The other patients are accounted for in 
studies that performed only pharmacokinetic analyses. 
 
In pediatric studies comparing ODD and traditional aminoglycoside regimens, clinical and 
microbiologic efficacy were similar between groups.
44–47
 Peak serum concentrations were 
significantly higher with ODD than with traditional regimens. It is difficult to determine if 
bactericidal activity was truly greater with ODD since none of these studies reported MIC values 
of infecting organisms.
44–47
 It cannot be concluded that ODD maximized clinical efficacy 
because of similar results in both treatment groups. 
 
Dosing regimens and patient populations must be reviewed before extrapolating clinical efficacy 
results of comparative studies into pediatric practice. An age-dependent dosing strategy for 
urinary tract infections was used in one study.44 Starting dosages of gentamicin were 4.5–7.5 
mg/kg/day, and adjustments were made in the traditionally dosed group to keep the peak serum 
concentration above 5 μg/ml. This traditional dosing regimen may be adequate for most urinary 
tract infections, as was illustrated in these children with clinical cure rates of 90–98%; however, 
the same dosages divided into three doses may not be sufficient for patients with more severe 
infections. 
 
Efficacy rates were similar (88–91%) in patients with suspected gram-negative bacterial 
infections.45 The urinary tract (46%) and laparotomy sites (52%) were primary sources of 
infection in this patient population. Therapy was begun with gentamicin 4.5 mg/kg/day; again, 
this dosage was adequate for the infections in these patients but may not be sufficient for many 
infectious processes in children such as gramnegative sepsis, bacteremia, and nosocomial 
infections. It is difficult to determine whether a more typical dosing approach (e.g., 7.5–9 
mg/kg/day) would have resulted in even greater efficacy in traditionally dosed patients in the 
above two studies. 
 
Failure rates were similar between ODD and traditional dosing regimens in patients with 
neutropenic fever.
47
 Patients failing to respond to initial therapy were changed from gentamicin 
to amikacin. No deaths were reported. Gentamicin 5 mg/kg/day was the dosage in the traditional 
arm rather than the more common starting dosage of 7.5 mg/kg/day. All patients received 
piperacillin in addition to gentamicin, which was general practice when an aminoglycoside was 
administered for neutropenic fever. Once-daily and twice-daily amikacin, both 20 mg/kg/day, 
yielded similar efficacy.
46
 A more appropriate traditional dosing interval would have been every 
8 hours rather than every 12 hours, given that the average age of patients in that treatment group 
was 5 years. Patients who failed to respond to amikacin were changed to ceftazidime. What is 
important to note in these two studies is that regardless of dosing regimen and concurrent 
antibiotics, treatment failures were similar between ODD and traditionally dosed 
aminoglycosides. In addition, it is difficult to detect whether ODD offered a change in true 
efficacy given that the traditional dose was not the most appropriate and that all children 
received an additional broad- spectrum antibiotic. 
 
Of nine studies that evaluated clinical and/or microbiologic efficacy, all but one administered 
concomitant antibiotics. Patients with uncomplicated urinary tract infections received 
monotherapy with gentamicin.
44
 The other eight studies administered a variety of 
cephalosporins, penicillins, and carbapenems as well as agents such as clindamycin and 
metronidazole.
45–52
 These additional antibiotics make it difficult to assess accurately the efficacy 
of extended-interval aminoglycoside monotherapy. Administering two or more antimicrobials for 
certain pediatric infections is consistent with current clinical practice. 
 
Of concern is the 36% failure rate for gramnegative infections in one trial.
50
 Pseudomonas sp 
accounted for 32% of these infections.50 Febrile patients with cancer with or without 
neutropenia received a combination of amikacin and ceftriaxone. Since ceftriaxone does not have 
reliable, if any, activity against Pseudomonas sp, an antipseudomonal β-lactam antibiotic would 
have been a more appropriate choice. 
 
There are few comparative data to assess efficacy of ODD versus traditional dosing in children, 
and available studies showed similar results. It is also difficult to extrapolate results of 
comparative studies to current practice because infections in the study populations did not 
represent the full range of pediatric infections encountered in clinical practice. Dosages in 
traditional regimens in a number of these trials were lower than recommended in common 
pediatric references.
27
 A number of pediatric studies evaluated only ODD and showed it to be 
both clinically and microbiologically effective. Whereas it is difficult to state decisively that 
ODD maximizes clinical and microbiologic efficacy based on the nine studies that determined 
efficacy, it can be concluded that ODD does seem to be an equally effective alternative to 
traditionally dosed aminoglycosides. 
 
One premise that ODD is based on is that nephrotoxicity is related to increased trough serum 
concentrations as well as duration of therapy and accumulation of drug. Therefore, an extended 
interval should result in lower or undetectable trough concentrations that could lead to less renal 
toxicity. All but one study evaluating nephrotoxicity used either an increase in serum creatinine 
or a decrease in creatinine clearance as safety end points, which are appropriate and common 
methods of evaluating potential nephrotoxicity in clinical practice. The remaining study reported 
no nephrotoxicity but did not discuss methods used to assess renal function.
52
 When looking at 
all studies of nephrotoxicity, no patients treated with a traditional aminoglycoside regimen met 
criteria for the disorder. The adverse effect was reported in four patients treated with ODD 
regimens.
49, 51, 53
 Studies comparing a traditional with a ODD regimen did not report 
nephrotoxicity in either group. Therefore, the theory that ODD produces less nephrotoxicity due 
to lower trough concentrations is not substantiated in pediatric studies. This may be due in part to 
increased clearance of aminoglycosides and to how well the drugs are tolerated in children. 
 
A prominent deficiency of studies evaluating ototoxicity was the number of patients evaluated. 
The overall ototoxicity rate was 3.5% in these studies, but only 57% and 56% of patients 
receiving ODD and traditionally dosed aminoglycosides were assessed at baseline and after 
discontinuation of therapy. There is a substantial difference in the frequency of ototoxicity when 
comparing the two regimens. The disorder occurred in 4.1% versus 2.4% of patients treated with 
ODD versus traditional dosing, respectively.
44, 45, 48, 49, 52–55
 That equates to a 71% difference 
between regimens when results of the eight studies are combined. Pediatric studies that assessed 
nephrotoxicity showed minimal difference between regimens, but the same cannot be said for 
ototoxicity. The study samples were relatively small, and not all patients had audiologic 
assessment, but the difference in frequency of ototoxicity is of concern. More data are required 
to make a sound conclusion regarding the effect of ODD on ototoxicity. 
 
Pharmacoeconomic effects may be associated with ODD. Potential cost savings may be realized 
in personnel time, drug and supply costs, preparation time, and serum concentration assays. This 
regimen also offers a more convenient method for administration of antibiotics at home. A 
hospital savings of $178.23/patient, or 66% reduction, was calculated when ODD regimens 
replaced standard regimens.
57
 The calculations took into account nursing and pharmacy staff 
time, drug and supply costs, monitoring of serum concentrations, and toxicity management, but 
not pharmacist time for monitoring patients. Another group estimated that ODD would result in 
an approximate saving of $14.64/patient/day in nursing charges and a cost avoidance of 
$64.50/patient each time drug concentrations were measured.
54 
 
Once-daily aminoglycoside dosing for children is an alternative, but not standard practice, in 
many hospitals. Some concerns are lack of pediatric data, increased aminoglycoside clearance in 
children, lack of standard dosing and/or dosing nomograms, and efficacy and safety. Two of the 
greatest concerns center on the efficacy of ODD as it relates to more rapid drug clearance in 
children and lack of a standard and accepted dosing approach. Daily doses in pediatric studies 
were 4.5–15 mg/kg for gentamicin and tobramycin and 15–20 mg/kg for amikacin. It is 
important to note that some of these dosages may be lower than what is commonly prescribed in 
traditional regimens. Thus a standard dosage for ODD cannot be extrapolated from these studies. 
 
Children with normal renal function eliminate aminoglycosides more rapidly than adults. In 
many instances it is feasible for a child receiving ODD to have a serum concentration below 
detectable limits for a significant portion of the dosing interval. Depending on the patient’s drug 
clearance and other patient characteristics, this time below detectable limits, or time below MIC, 
could range from a few hours to 12–16 hours. Whereas aminoglycoside antibiotics do benefit 
from a PAE, the duration of the PAE in animal and in vitro human models ranged from 1–8 and 
1–2 hours, respectively.30–32 In a mouse model bacteria regrew and reached initial infection 
levels approximately 6 hours after a single high dose of netilmicin, even in the presence of a 
PAE.
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Is efficacy being compromised when the serum concentration is allowed to remain undetectable 
for a significant period of time, given this indication of bacterial regrowth? Results of limited 
pediatric studies indicate that efficacy was not compromised in most patients receiving ODD. As 
mentioned, these comparisons were compromised in some cases by inappropriate dosages in 
traditional regimens. In addition, aminoglycosides rarely are given for monotherapy for 
suspected or confirmed gram-negative bacteremia; in such children they typically are combined 
with a β-lactam antibiotic. 
 One response to the concern of compromised efficacy when serum concentrations remain 
undetectable for long periods of time could be to shorten the dosing interval according to a 
dosing nomogram similar to the Hartford nomogram. How long the serum concentration can 
remain below detectable limits before a change in dosing interval is necessary is not known and 
must be determined before a nomogram can be developed and tested. Another option would be 
for clinicians to revert to traditional dosing. This would seem logical when serum concentrations 
are undetectable for prolonged durations or when patients respond poorly. However, such a 
change could make achieving preferred peak:MIC ratios difficult in patients with intermediately 
susceptible bacterial infections. 
 
Conclusion 
 
Although data for aminoglycoside ODD in children include only approximately 700 patients, 
most results indicate that this method is as effective as traditional dosing. More safety data are 
required in children, however, since only 75% and 56% of patients receiving ODD had an 
adequate nephrotoxicity or ototoxicity assessment, respectively. It is important to consider study 
limitations when evaluating the overall efficacy and safety of ODD in children. The comparative 
studies are limited by small samples, use of traditional dosages that are lower than those in 
current practice, lack of routine assessment of baseline and posttreatment auditory and vestibular 
function, and limited number of patients with documented gramnegative bacteremia. 
 
Once-daily aminoglycoside dosing appears to be appropriate and effective as monotherapy for 
uncomplicated urinary tract infections and for treatment or prevention of surgical infections. It 
should be considered when the drug is administered with an appropriate β-lactam antibiotic (with 
or without anaerobic coverage). In addition, ODD appears to be appropriate in combination with 
an antipseudomonal antibiotic for fever and neutropenia. Given the clinical practice of 
administering concomitant antibiotics with aminoglycosides for gram-negative bacteremia in 
children, ODD could be an acceptable alternative in this population. However, additional studies 
must be performed in patients with gram-negative bacteremia, sepsis, and/or septic shock before 
it can be recommended consistently. This regimen appears appropriate in combination with an 
antipseudomonal antibiotic for patients with cystic fibrosis. However, these patients may require 
higher dosages to achieve a peak: MIC ratio of 8–10:1 based on a higher distribution volume and 
the potential for intermediately susceptible or resistant microorganisms. Once daily dosing 
should not be used in pediatric burn patients, given altered pharmacokinetics of aminoglycosides 
and lack of data of ODD in this population. In addition, it should not be used in children with 
abnormal renal function. 
 
Based on dosages in available studies and on population pharmacokinetic parameters at the 
authors’ practice sites, gentamicin or tobramycin 7–8 mg/kg every 24 hours is recommended as 
initial therapy in children with conditions other than cystic fibrosis. Based on population 
pharmacokinetics at our practice sites, this dosage is estimated to achieve a peak concentration of 
20 μg/ml and trough concentrations of less than 1 μg/ml. A goal peak concentration of 20 μg/ml 
was chosen so that a peak:MIC ratio of 10:1 would be attained for an organism with an MIC of 2 
μg/ml to gentamicin or tobramycin. A recommendation for amikacin ODD cannot be made at 
this time. 
 Since dosing nomograms are not available for use with children, serum concentrations should be 
monitored. For patients receiving ODD with an anticipated duration of treatment less than 72 
hours, a concentration before the second dose should be measured to ensure that the trough 
concentration is less than 1 μg/ml. For patients receiving ODD with an anticipated duration of 
treatment greater than 72 hours, two options are available. One is to measure a concentration 
before the second dose as above. Also, a peak concentration obtained 30 minutes after the end of 
the infusion of the second dose should be drawn to ensure a peak: MIC ratio of 8–10:1. The 
second option is to measure a peak concentration 30 minutes after the end of the infusion of the 
first dose to ensure that it is adequate. A midinterval serum concentration 8–10 hours after the 
first dose should be measured to extrapolate a trough concentration. For patients without a 
positive culture and therefore no MIC data, the peak concentration should be maintained between 
16 and 20 μg/ml. 
 
Safety of aminoglycoside therapy should be monitored for both ODD and traditionally dosed 
regimens. Serum creatinine should be monitored at baseline and frequently thereafter for 
nephrotoxicity. In addition, urine output is a good clinical indicator of renal function and should 
be monitored daily. Consideration should be given to changing the dose and/or interval, or 
measuring serum concentrations if there is a clinically significant increase in serum creatinine or 
decrease in urine output from baseline. Ideally, audiometric assessments would be completed 
before starting and at some point during therapy. However, this is not always clinically feasible 
given the frequency with which these drugs are administered to children. Close monitoring for 
nephrotoxicity and ototoxicity is necessary in patients with cystic fibrosis due to the number of 
aminoglycoside treatment courses they receive. Dose-finding studies with a focus on nomogram 
development as well as safety and efficacy assessment should be performed in large samples of 
children to answer some of the clinically relevant and currently unanswered questions. 
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